降逆胃舒汤治疗萎缩性胃炎疗效及对患者病理评分的影响

目的:研究降逆胃舒汤对幽门螺杆菌感染致萎缩性胃炎病理评分的功效。方法:选取238例幽门螺杆菌感染致萎缩性胃炎患者作为本次研究观察对象,入选患者遵循随机数字表法平均分配入对照组与治疗组,对照组以常规西药四联疗法治疗,治疗组在对照组疗法的基础上给予降逆胃舒汤治疗; 治疗3个月后,观察两组患者HP清除率并随访6个月统计复发率,观察两组患者中医证候积分、胃黏膜胃镜征象积分、胃黏膜病理评分及血清胃泌素-17(G-17)、血清胃蛋白酶原Ⅰ、Ⅱ(PGⅠ、PGⅡ)、PGⅠ/PGⅡ比值(PGR)治疗前、后的变化情况。结果:治疗前两组患者各项中医证候、胃黏膜胃镜积分、病理评分及血清指标表达水平比较,差异无统计学意义(P>0.05); 治疗后两组患者各项中医证候、胃黏膜胃镜积分、病理评分及血清指标表达水平比较,差异有统计学意义(P<0.05),治疗组均优于对照组(P<0.05); 治疗后3个月时治疗组HP清除率为88.24%、对照组为73.11%,随访6个月治疗组复发率为3.81%,对照组为18.39%,两组HP根除率、复发率比较,差异有统计学意义(P<0.05)。结论:降逆胃舒汤能够提高幽门螺杆菌清除率并降低复发,更有效缓解幽门螺杆菌感染致萎缩性胃炎的各项中医证候,进一步改善患者胃黏膜病理评分与胃镜征象,更良好的调节患者血清指标。     

Inverse correlation between gastroesophageal reflux disease and atrophic gastritis assessed by endoscopy and serology

BACKGROUND Helicobacter pylori(H.pylori)infection is known to prevent the occurrence of gastroesophageal reflux disease(GERD)by inducing gastric mucosal atrophy.However,little is known about the relationship between atrophic gastritis(AG)and GERD.AIM To confirm the inverse correlation between AG and the occurrence and severity of GERD.METHODS Individuals receiving health checkups who underwent upper gastrointestinal endoscopy at Seoul National University Healthcare System Gangnam Center were included.The grade of reflux esophagitis was evaluated according to the Los Angeles classification.Endoscopic AG(EAG)was categorized into six grades.Serologic AG(SAG)was defined as pepsinogen I≤70 ng/m L and pepsinogen I/II ratio≤3.0.The association between the extent of EAG and SAG and the occurrence and severity of GERD was evaluated using multivariate logistic regression analysis.RESULTS In total,4684 individuals with GERD were compared with 21901 healthy controls.In multivariate logistic regression analysis,advanced age,male sex,body mass index>23 kg/m2,presence of metabolic syndrome,current smoking,and alcohol consumption were associated with an increased risk of GERD.Seropositivity for H.pylori immunoglobulin G antibodies was associated with a decreased risk of GERD.There was an inverse correlation between the extent of EAG and occurrence of GERD:Odds ratio(OR),1.01[95%confidence interval(CI):0.90-1.14]in C1,0.87(0.78-0.97)in C2,0.71(0.62-0.80)in C3,0.52(0.44-0.61)in O1,0.37(0.29-0.48)in O2,and 0.28(0.18-0.43)in O3.Additionally,the extent of EAG showed an inverse correlation with the severity of GERD.The presence of SAG was correlated with a reduced risk of GERD(OR=0.49,95%CI:0.28-0.87,P=0.014).CONCLUSION The extent of EAG and SAG exhibited strong inverse relationships with the occurrence and severity of GERD.AG followed by H.pylori infection may be independently protect against GERD.     

Significance of pepsinogen in screening for gastric intestinal metaplasia in Guangdong,China

ObjectiveDiagnosis of gastric intestinal metaplasia (GIM) relies on gastroscopy and histopathologic biopsy, but their application in screening for GIM is limited. We aimed to identify serological biomarkers of GIM via screening in Guangdong, China.MethodsCross-sectional field and questionnaire data, demographic information, past medical history, and other relevant data were collected. Blood samples were collected for pepsinogen (PG)I, PGII, gastrin-17, and Helicobacter pylori antibody testing, and gastroscopy and histopathologic biopsy were performed. Single factor and logistic regression analyses were used to evaluate the correlation between these indicators and GIM, and decision tree models were used to determine the cut-off points between indicators.ResultsOf 443 participants enrolled, 87 (19.6%) were diagnosed with GIM. Single factor analysis showed that pepsin indicators (PGI, PGII, and PGI/PGII ratio) and the factors Mandarin as native language, urban residency, hyperlipidemia, and age were associated with GIM. Logistic regression analysis showed that PGI and age were associated with GIM.ConclusionsAge is an important factor for predicting GIM progression; age >60 years increased its risk. Detection of GIM was higher in individuals with PGI levels >127.20 ng/mL, which could be used as a threshold indicating the need to perform gastroscopy and histopathologic biopsy.     

胃蛋白酶原、胃泌素 –17 与 GERD 病情进展的关系

〔摘 要〕 目的：探究胃蛋白酶原、胃泌素 –17 与胃食管反流（GERD）病情进展的关系。 方法：选取惠州市中医医院 2019 年 2 月至 2021 年 2 月期间收治的 150 例 GERD 患者,按检查结果分为非糜烂性食管炎（NERD）组、糜烂性食管炎（EE） 组和 Barrett 食管（BE）组,各 50 例,使用量子点荧光免疫分析法检测血清胃蛋白酶原 Ⅰ、Ⅱ 及胃泌素 –17 水平,分析其与 GERD 严重程度的相关性。并采用受试者工作特征曲线（ROC）分析血清胃蛋白酶原 Ⅰ、Ⅱ 及胃泌素 –17 诊断 GERD 的效能。 结果：三组患者血清胃蛋白酶原 Ⅰ 及胃泌素 –17 水平：BE 组＞ EE 组＞ NERD 组,胃蛋白酶原 Ⅱ 水平：NERD 组＞ EE 组 ＞ BE 组,差异具有统计学意义（P ＜ 0.05）;胃蛋白酶原 Ⅰ、胃泌素 –17 与 GERD 严重程度呈正相关,差异具有统计学意义 （P ＜ 0.05）。胃蛋白酶原 Ⅱ 与 GERD 严重程度呈负相关,差异具有统计学意义（P ＜ 0.05）;ROC 结果显示,胃蛋白酶 原 Ⅰ 截断值为＞ 136.98 μg·L-1,诊断 GERD 曲线下面积 0.788,灵敏度 84.00 %,特异度 74.00 %;胃蛋白酶原 Ⅱ 截断值为 ≤ 7.99 μg·L-1,诊断 GERD 曲线下面积 0.698,灵敏度 70.00 %,特异度 78.00 %;胃泌素 –17 截断值为＞ 2.55 pmol·L-1 , 诊断 GERD 曲线下面积 0.848,灵敏度 85.00 %,特异度 88.00 %。 结论：GERD 患者随着病情进展,胃蛋白酶原 Ⅰ 及胃泌素 –17 水平上升,胃蛋白酶原 Ⅱ 降低,且以上指标诊断 GERD 的灵敏度与特异度较高,因其具有方便、廉价的优点,有望成为筛 查 GERD 的血清学指标。     

胃蛋白酶原，胃泌素测定在胃癌诊断中的应用研究

[目的]探讨胃蛋白酶原Ⅰ（PGⅠ）、胃蛋白酶原Ⅱ（PGⅡ）、胃泌素（GS）水平变化对胃癌的诊断价值。[方法]应用免疫放射分析法测定了100例正常人，66例胃癌、107例胃溃疡，101例慢性胃炎患者血清PGⅠ、PGⅡ、GS含量及PGⅠ／PGⅡ比值的变化。[结果]胃癌组血清PGⅠ、PGI／PGⅡ水平较对照组显著降低（〈0．001），PGⅡ水平较对照组无显著变化（P〉0．05），GS水平较对照、慢性胃炎组和溃疡病组组明显增高（P〈0．001）。[结论]血清PGⅠ和PGⅠ／PGⅡ比值下降，GS增高是与胃癌发生密切相关的高危因素，可作为诊断胃癌的一项血清学指标，对胃癌的诊断有一定的临床意义。     

胃癌高发地区慢性萎缩性胃炎血清幽门螺杆菌抗体分型情况以及癌变风险的差异

目的分析胃癌高发地区慢性萎缩性胃炎( CAG)病人血清幽门螺杆菌( Hp)抗体分型情况以及癌变风险的差异。方法纳入 2019年 12月至 2021年 1月合肥市第二人民医院就诊的 168例 CAG病人作为研究对象,采用蛋白质印迹法检测血清 Hp抗体分型( CagA、VacV、Ure),分为 Ⅰ型 Hp组、 Ⅱ型 Hp组和阴性组;酶联免疫吸附测定( ELISA)检测胃黏膜功能［胃蛋白酶原( PG)Ⅰ、PGⅡ、胃蛋白酶原比值( PRG)、胃泌素 17(G17)］采用“改良 ABC法”进行癌变风险分层,参考“木村 -竹本”分类法对萎缩范围分级,根据萎缩部位和程度进行 OLGA分期。结果,168例 CAG病人中 Ⅰ型 Hp组 83例, Ⅱ型 Hp组 39例, Hp阴性 46例;单纯胃窦萎缩病人, I型 Hp病人 G17低于 Ⅱ型和 Hp阴性组［3.61(2.57,5.04)pmol/L比 5.85(3.91,7.32)pmol/L,6.01(4.55, 8.39)pmol/L,P<0.05］;胃窦 +胃体萎缩病人, I型 Hp病人 PGⅠ［82.66(61.00,101.28)μg/L比 100.27(66.59,124.28)μg/L,98.04(70.22,121.43)μg/L］、 PRG［8.55(7.16,11.02)比 10.13(8.94,12.31)10.71(9.08,13.16)］低于 Ⅱ型和 Hp阴性组( P<0.05);三组“改良 ABC”癌变风险分层差异有统计学意义( P<0.05)其中 Ⅰ型 Hp病,人高危层占比最高,达 33.74%;三组“木村 -竹本”分类法 “C型”“O型”的比例差异无统计学意义［18.72%(15/83,)比 23.07%(9/39),13.04%(6/46),P>0.05］;三组 OLGA分期差异有统计学意义(和P<0.05),I型 Hp病人 Ⅲ期和 Ⅳ期共 19例,占比最高( 22.89%)但三组间对比显示, I型和 Ⅱ型 Hp病人间 OLGA分组差异无统计学意义( P>0.017)I型 Hp病人 OLGA高危组占比高于 Hp阴性,病人( P<0.017)。结论胃癌高发地区 CAG病人以 Ⅰ型 Hp感染多见,不同分型 Hp感,染的 CAG病人 PG、PGR、G17水平存在差异, Ⅰ型 Hp感染的 CAG病人癌变风险相对较高。     

不安运动阶段对早产儿运动发育结局的预测价值

目的比较全身运动质量评估(General movements assessment,GMs)不安运动阶段和Gesell发育量表(Gesell Developmental Test Scales,GDS)对早产儿运动发育结局的预测效度,及对两种评估方法和发育结局的一致性检测。方法对2011年6月-2013年6月共226例在本院儿童保健科随访的早产儿,在纠正5个月内采用GMs和GDS进行评估,在纠正12个月时临床诊断是否为脑瘫,并使用Peabody运动发育量表(Peabody Development Motor Scale 2,PDMS-2)确定其运动发育结局。对比分析两种评估方法的预测效度(包括敏感度、特异度、阳性预测值和阴性预测值),及与发育结局的相关性。结果 226例早产儿发育结局中运动发育正常176例,运动发育迟缓22例,脑瘫28例。不安运动阶段评估结果为正常者168例,异常为58例;GDS评估结果为正常者140例,异常为86例。不安运动及GDS预测脑瘫敏感度92.9%、71.4%,特异度83.8%、66.7%,阳性预测值44.8%、23.3%,阴性预测值98.8%、94.3%。不安运动及GDS预测运动发育结局敏感度88.0%、68.0%,特异度92.0%、70.4%,阳性预测值75.9%、39.5%,阴性预测值96.4%、88.6%。GDS和PDMS-2的一致性检验Kappa值0.306,P0.05,GMs和PDMS-2评估的一致性检验Kappa值0.757,P0.05,提示GMs、GDS对运动发育预测与发育结局均具有良好的一致性,GMs中不安运动阶段的预测与发育结局的一致性更高。结论 GMs的不安运动阶段能够超早期预测脑瘫等不良运动发育结局,在预测预后方面要优于GDS,能更早期的做出预测。     

短波紫外线与交联淀粉碘联用法对血浆中病毒灭活的研究

采用细胞感染试验、全自动生化分析仪、ＳＤＳ－ＰＡＧＥ等技术，观察短波紫外线（ＵＶＣ）与交联淀粉碘（ＣＳＩ）联用对血浆中辛德比斯病毒（ＳＶ）的灭活效果及血浆成分的变化。结果，以７１７０Ｊ／ｍ２ＵＶＣ照射后再经１００ｍｇ／ｍｌＣＳＩ处理６０ｍｉｎ，血浆中病毒的灭活可达６个对数级，且两消毒因子有协同增效作用。消毒后的血浆，除乳酸脱氢酶完全消失，总胆红素含量明显下降，钾离子含量比对照增加５２倍外，多种蛋白含量、蛋白分子量和生化指标均维持在正常值范围。     

Diagnosis of gastritis by means of a combination of serological analyses

Background: Gastroscopy and examination of biopsy is normally required for diagnosis of gastritis. This is costly and inconvenient for the patient, and there is a need for a simple pregastroscopic screening method to reduce the endoscopy workload. Our aim was to develop a serological screening test for gastritis. Methods: Sera from subjects examined with gastroscopy and biopsy were analyzed for H,K-ATPase antibodies, Helicobacter pylori antibodies and pepsinogen I. The diagnoses were normal gastric mucosa (n=50), duodenal ulcer (n=53) and atrophic corpus gastritis, with (n=50) or without pernicious anemia (n=46). Results: An evaluation scheme was constructed to optimize the diagnostic agreement between serology and gastric mucosal morphology. The sensitivity to detect gastritis was 98% (146/149) (95% CI 94–100%) and the specificity 84% (42/50) (95% CI 71–93%). Additional sera from 483 subjects from the general population were analyzed. There was a good agreement between serology and gastric mucosal morphology. Conclusions: Assays of multiple serum analytes are useful for the initial screening of gastritis. They are complementary to upper gastroscopy by identification of subjects with a normal gastric mucosa, those who qualify for eradication of H. pylori, and those who have developed atrophy and are at risk of developing malignancy and, therefore, require gastroscopic examination.